Elefant Dov
Known title: Chief Financial OfficerCIK: 0001326487
Elefant Dov's purchase track record
Elefant Dov has no open-market purchases with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 8/7/2026 | FEMY | $50K | pending | pending | — |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Transaction History
| FEMY | ▲ Buy | Open Market | 15,625 | $50K | 8/7/2026 | View on chart |
| FEMY | ▼ Sell | Other | 38,828 | — | 8/27/2025 | View on chart |
| FEMY | ▼ Sell | Other | 19,608 | $20K | 6/2/2025 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 9, 2026
Femasys to Showcase FemaSeed at ASRM 2026
Femasys announced it will exhibit its FemaSeed fertility treatment at the ASRM 2026 Scientific Congress & Expo. This move signals an expansion of the company's commercialization strategy as it seeks to increase visibility for its product. The stock currently trades near its 52-week low, with an RSI of 36.7 indicating recent weakness.
Femasys to Showcase FemaSeed at ASRM 2026. Femasys announced it will exhibit its FemaSeed fertility treatment at the ASRM 2026 Scientific Congress & Expo. This move signals an expansion of the company's commercialization strategy as it seeks to increase visibility for its product. The stock currently trades near its 52-week low, with an RSI of 36.7 indicating recent weakness.